These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 16773620)

  • 41. Estimation of resource utilization associated with osteoporotic hip fracture and level of post-acute care in China.
    Dai K; Zhang Q; Fan T; Sen SS;
    Curr Med Res Opin; 2007 Dec; 23(12):2937-43. PubMed ID: 17931462
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The economic impact of cognitive impairment in Parkinson's disease.
    Vossius C; Larsen JP; Janvin C; Aarsland D
    Mov Disord; 2011 Jul; 26(8):1541-4. PubMed ID: 21538519
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Costs and quality of life for patients with multiple sclerosis in Belgium.
    Kobelt G
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Analysis on direct economic burden of community COPD patients and its influence factors in Chengdu].
    Zhang B; Zhang Y; Yang J; Liu X
    Wei Sheng Yan Jiu; 2007 Nov; 36(6):706-10. PubMed ID: 18303632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Health-economic burden of Parkinson's disease in Portugal: a cohort study].
    Reese JP; Winter Y; Rosa MM; Rodrigues E Silva AM; von Campenhausen S; Freire R; Mateus C; Balzer-Geldsetzer M; Botzel K; Oertel WH; Dodel R; Sampaio C
    Rev Neurol; 2011 Mar; 52(5):264-74. PubMed ID: 21341221
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.
    Chiang CH
    Respirology; 2008 Sep; 13(5):689-94. PubMed ID: 18513247
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The cost of systemic sclerosis.
    Bernatsky S; Hudson M; Panopalis P; Clarke AE; Pope J; Leclercq S; St Pierre Y; Baron M;
    Arthritis Rheum; 2009 Jan; 61(1):119-23. PubMed ID: 19116974
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.
    Nuijten MJ; van Iperen P; Palmer C; van Hilten BJ; Snyder E
    Value Health; 2001; 4(4):316-28. PubMed ID: 11705299
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The economic impact of Parkinson's disease.
    Findley LJ
    Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S8-S12. PubMed ID: 17702630
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Analysis on direct economic burden of stroke in the rural population of Hanzhong, Shaanxi Province].
    Long Y; Lu J; Xu DZ; Hu JX; Jiang JH; Yan YP; Huang JY; Yang J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2005 Jul; 26(7):494-7. PubMed ID: 16334999
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Parkinson's disease and hospital admissions: frequencies, diagnoses and costs.
    Vossius C; Nilsen OB; Larsen JP
    Acta Neurol Scand; 2010 Jan; 121(1):38-43. PubMed ID: 19744137
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Costs and quality of life of multiple sclerosis in Austria.
    Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Economic burden of endometriosis.
    Gao X; Outley J; Botteman M; Spalding J; Simon JA; Pashos CL
    Fertil Steril; 2006 Dec; 86(6):1561-72. PubMed ID: 17056043
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative cost analysis of outpatient and inpatient rehabilitation for musculoskeletal diseases in Germany.
    Zeidler J; Mittendorf T; Vahldiek G; Zeidler H; Merkesdal S
    Rheumatology (Oxford); 2008 Oct; 47(10):1527-34. PubMed ID: 18682412
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Costs and quality of life of multiple sclerosis in Spain.
    Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Economic costs of diabetes in the U.S. In 2007.
    American Diabetes Association
    Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The current and projected economic burden of Parkinson's disease in the United States.
    Kowal SL; Dall TM; Chakrabarti R; Storm MV; Jain A
    Mov Disord; 2013 Mar; 28(3):311-8. PubMed ID: 23436720
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Economic burden of coronary heart disease and stroke attributable to hypertension in China].
    Zhai Y; Hu JP; Kong LZ; Zhao WH; Chen CM
    Zhonghua Liu Xing Bing Xue Za Zhi; 2006 Sep; 27(9):744-7. PubMed ID: 17299955
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The prevalence and pharmacological cost of Parkinson's disease in Spain].
    Abasolo-Osinaga E; Abecia-Inchaurregui LC; Fernández-Díaz E; Barcenilla-Laguna A; Bañares-Onraita T
    Rev Neurol; 2006 Dec 1-15; 43(11):641-5. PubMed ID: 17133323
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment.
    Chen JJ
    Am J Manag Care; 2010 Mar; 16 Suppl Implications():S87-93. PubMed ID: 20297871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.